The company later focused on developing more potent synthetic activators of SIRT1 and is investigating SIRT3 as another potential drug target.
Torrent Pharmaceuticals | Emcure Pharmaceuticals | Barr Pharmaceuticals | Valeant Pharmaceuticals | Reata Pharmaceuticals | Millennium Pharmaceuticals | Anthera Pharmaceuticals | Quark Pharmaceuticals | Norwich Pharmaceuticals | Incepta Pharmaceuticals | Glenmark Pharmaceuticals |